MedTrace Logo

Cytochrome C Oxidase Activity in Newly Diagnosed Glioblastoma Multiforme (GBM)

NCT02997423 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 153

Last updated 2023-02-13

No results posted yet for this study

Summary

This is a multi-institutional, consortium-based, non-interventional prospective blinded endpoints clinical study to determine whether high activity of Cytochrome C Oxidase (CcO) in tumor specimens from subjects with newly diagnosed primary GBM is associated with shortened OS (primary outcome) and PFS (secondary outcome) times.

Conditions

Sponsors & Collaborators

  • National Institute of Neurological Disorders and Stroke (NINDS)

    collaborator NIH

  • NeuroNEXT Network

    collaborator OTHER

  • University of Iowa

    lead OTHER

Principal Investigators

  • Corinne E Griguer, PhD · University of Iowa

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-30
Primary Completion
2022-11-30
Completion
2022-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02997423 on ClinicalTrials.gov